ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

BACKGROUND: Bevacizumab improves outcome and reduces symptoms in patients with recurrent glioblastoma (GBM). However, GBMs develop adaptive resistance to bevacizumab- mediated angiogenesis inhibition resulting in tumor recurrence. We hypothesized that vorinostat, a histone deacetylase (HDAC) inhibit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Principais autores: Puduvalli, Vinay, Wu, Jing, Yuan, Ying, Armstrong, Terri, Wu, Jimin, Giglio, Pierre, Xu, Jihong, Colman, Howard, Walbert, Tobias, Raizer, Jeffrey, Groves, Morris, Iwamoto, Fabio, Tran, David, Avgeropoulos, Nicholas, Paleologos, Nina, Fink, Karen, Peereboom, David, Chamberlain, Marc, Merrell, Ryan, Penas-Prado, Marta, Yung, W K Alfred, Gilbert, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216165/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.047
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados